Division of Metabolism, Systemic Bioscience, Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan; Department of General Medicine, Asahikawa Medical University, Japan.
Department of Regional Medicine and Education, Asahikawa Medical University, Japan.
Exp Neurol. 2021 Jul;341:113708. doi: 10.1016/j.expneurol.2021.113708. Epub 2021 Mar 23.
Leaky gut that is a condition reflecting intestinal barrier dysfunction has been attracting attention for its relations with many diseases such as irritable bowel syndrome or Alzheimer dementia. We have recently demonstrated that ghrelin acts in the brain to improve leaky gut via the vagus nerve. In the present study, we tried to clarify the precise central mechanisms by which ghrelin improves intestinal barrier function through the vagus nerve. Colonic permeability was estimated in vivo by quantifying the absorbed Evans blue in colonic tissue in rats. Adenosine receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), blocked the intracisternal ghrelin-induced improvement of intestinal hyperpermeability while dopamine, cannabinoid or opioid receptor antagonist failed to prevent it. Since DPCPX can block adenosine A1 and adenosine A2B receptors, we examined which subtype is involved in the mechanism. Intracisternal injection of adenosine A2B agonist but not adenosine A1 agonist improved colonic hyperpermeability, while peripheral injection of adenosine A2B agonist failed to improve it. Intracisternal adenosine A2B agonist-induced improvement of colonic hyperpermeability was blocked by vagotomy. Adenosine A2B specific antagonist, alloxazine blocked the ghrelin- or central vagal stimulation by 2-deoxy-d-glucose-induced improvement of intestinal hyperpermeability. These results suggest that activation of adenosine A2B receptors in the central nervous system is capable of improving intestinal barrier function through the vagal pathway, and the adenosine A2B receptors may mediate the ghrelin-induced improvement of leaky gut in a vagal dependent fashion. These findings may help us understand the pathophysiology in not only gastrointestinal diseases but also non-gastrointestinal diseases associated with the altered intestinal permeability.
肠漏,即肠道屏障功能障碍的一种表现,因其与肠易激综合征或阿尔茨海默病等多种疾病有关而受到关注。我们最近的研究表明,ghrelin 通过迷走神经作用于大脑,改善肠漏。在本研究中,我们试图通过迷走神经阐明 ghrelin 改善肠道屏障功能的精确中枢机制。通过定量大鼠结肠组织中吸收的 Evans 蓝来评估结肠通透性。腺苷受体拮抗剂 1,3-二丙基-8-环戊基黄嘌呤(DPCPX)阻断了脑室内 ghrelin 诱导的肠道高通透性的改善,而多巴胺、大麻素或阿片受体拮抗剂则不能阻止这种改善。由于 DPCPX 可以阻断腺苷 A1 和腺苷 A2B 受体,我们研究了哪种亚型参与了这种机制。脑室内注射腺苷 A2B 激动剂可改善结肠高通透性,而外周注射腺苷 A2B 激动剂则不能改善。迷走神经切断术阻断了脑室内腺苷 A2B 激动剂诱导的结肠高通透性改善。腺苷 A2B 特异性拮抗剂,别嘌呤醇阻断了 ghrelin 或中枢迷走神经刺激通过 2-脱氧-d-葡萄糖诱导的肠道高通透性改善。这些结果表明,中枢神经系统中腺苷 A2B 受体的激活通过迷走神经途径能够改善肠道屏障功能,而腺苷 A2B 受体可能介导 ghrelin 诱导的肠漏改善的迷走神经依赖方式。这些发现可能有助于我们理解不仅是胃肠道疾病,而且是与改变的肠道通透性相关的非胃肠道疾病的病理生理学。